November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
January 2024 in “Bulletin of Medical Science” Pantotherapy is more effective for treating androgenetic alopecia than darsonvalization.
11 citations
,
August 1948 in “Journal of Investigative Dermatology” Calcium pantothenate therapy improved symptoms of discoid lupus erythematosus without side effects.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
35 citations
,
July 2008 in “International Journal of Gynecology & Obstetrics” MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Higher doses of spironolactone may improve acne in PCOS patients, but side effects are a concern.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
January 2011 in “Kazan medical journal” Both finasteride and drospirenone effectively manage PCOS symptoms, but drospirenone is more effective in reducing ovarian volume and androgen levels.
5alpha-DHP may be a safe, effective treatment for certain seizures without causing sedation.
August 2025 in “Journal of the American Academy of Dermatology” 111 citations
,
February 1991 in “Headache The Journal of Head and Face Pain” Valproate significantly improved headaches in two-thirds of patients.
3 citations
,
October 2024 in “Advances in Therapy” Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
May 2024 in “News Digital Object Group”
June 2021 in “Clinical neuropsychopharmacology and therapeutics” Valproic acid can cause hair color change in older men.
Letrozole combined with Cabergoline improves ovulation and pregnancy rates in women with PCOS and high prolactin levels compared to Letrozole alone.
September 2004 in “Inpharma Weekly” 39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
14 citations
,
October 2006 in “Journal of The American Academy of Dermatology” A woman with Parkinson's disease experienced hair loss from the Parkinson's medication pramipexole, which improved after stopping the drug.
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
36 citations
,
May 2005 in “BMC dermatology” DPCP is effective for treating severe alopecia areata, but relapse is common.
7 citations
,
January 2018 in “Reproduction” Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.